Jens T. Siveke

Comparison of 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography (FLT PET) and FDG PET/CT for the detection and characterization of pancreatic tumours

H. Friess, M. Schwaiger, A. Buck, 2012, European Journal of Nuclear Medicine and Molecular Imaging.

Oncologic Staging with 68Ga-FAPI PET/CT Demonstrates a Lower Rate of Nonspecific Lymph Node Findings Than 18F-FDG PET/CT

L. Umutlu, K. Herrmann, K. Pomykala, 2023, The Journal of Nuclear Medicine.

Histology-Based Radiomics for [18F]FDG PET Identifies Tissue Heterogeneity in Pancreatic Cancer

M. Trajkovic-Arsic, E. Aarntzen, D. Geijs, 2024, The Journal of Nuclear Medicine.

68Ga-Labeled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the 68Ga-FAPI PET Observational Trial

N. Hirmas, J. Ferdinandus, L. Kessler, 2023, The Journal of Nuclear Medicine.

Prognostic Implications of 68Ga-FAPI-46 PET/CT–Derived Parameters on Overall Survival in Various Types of Solid Tumors

N. Hirmas, H. Grafe, B. von Tresckow, 2024, The Journal of Nuclear Medicine.

Diagnostic Accuracy of 68Ga-FAPI Versus 18F-FDG PET in Patients with Various Malignancies

N. Hirmas, C. Kesch, L. Kessler, 2024, Journal of Nuclear Medicine.